CA3073576C - Use of cannabidiol in preparation of drugs for resisting against influenza - Google Patents

Use of cannabidiol in preparation of drugs for resisting against influenza Download PDF

Info

Publication number
CA3073576C
CA3073576C CA3073576A CA3073576A CA3073576C CA 3073576 C CA3073576 C CA 3073576C CA 3073576 A CA3073576 A CA 3073576A CA 3073576 A CA3073576 A CA 3073576A CA 3073576 C CA3073576 C CA 3073576C
Authority
CA
Canada
Prior art keywords
influenza
virus
subtype
cannabidiol
extract containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3073576A
Other languages
English (en)
French (fr)
Other versions
CA3073576A1 (en
Inventor
Ke Zhang
Xin Tan
Xiangdong Li
Zhaohui Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanyi Bio-Technology Co Ltd
Original Assignee
Hanyi Bio-Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanyi Bio-Technology Co Ltd filed Critical Hanyi Bio-Technology Co Ltd
Publication of CA3073576A1 publication Critical patent/CA3073576A1/en
Application granted granted Critical
Publication of CA3073576C publication Critical patent/CA3073576C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Botany (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
CA3073576A 2017-08-31 2017-08-31 Use of cannabidiol in preparation of drugs for resisting against influenza Active CA3073576C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/099956 WO2019041239A1 (zh) 2017-08-31 2017-08-31 大麻二酚在制备抗流感的药物中的用途

Publications (2)

Publication Number Publication Date
CA3073576A1 CA3073576A1 (en) 2019-03-07
CA3073576C true CA3073576C (en) 2023-01-24

Family

ID=65524611

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3073576A Active CA3073576C (en) 2017-08-31 2017-08-31 Use of cannabidiol in preparation of drugs for resisting against influenza

Country Status (6)

Country Link
US (1) US11452707B2 (enExample)
EP (1) EP3677258B1 (enExample)
JP (1) JP6963719B2 (enExample)
AU (1) AU2017429312B2 (enExample)
CA (1) CA3073576C (enExample)
WO (1) WO2019041239A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113116867B (zh) * 2019-12-31 2022-08-23 汉义生物科技（北京）有限公司 一种预防和/或治疗流感的组合物
CN111249266B (zh) * 2020-03-06 2022-08-09 中国人民解放军海军军医大学 帕拉米韦在制备治疗感染性疾病引起炎症风暴的药物中的应用
DK181405B1 (en) * 2021-05-25 2023-10-17 Cs Medica As Gel for Intranasal Application, its Provision and Use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110091780A (ko) * 2008-11-25 2011-08-12 앨더 바이오파마슈티컬즈, 인코포레이티드 악액질, 쇠약, 피로 및／또는 발열을 예방하거나 치료하는 ｉｌ­６의 길항제
FR2953410B1 (fr) * 2009-12-09 2012-02-24 Univ Claude Bernard Lyon Compositions antivirales pharmaceutiques ou veterinaires
US20130203715A1 (en) * 2010-07-20 2013-08-08 Pulmatrix, Inc. Use of trp channel agonists to treat infections
US9308213B2 (en) * 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
GB201018289D0 (en) * 2010-10-29 2010-12-15 Biocopea Ltd Treatment of respiratory disorders
WO2012104655A2 (en) * 2011-02-04 2012-08-09 Biocopea Limited Compostions and methods for treating chronic inflammation and inflammatory diseases
WO2016092539A1 (en) * 2014-12-07 2016-06-16 One World Cannabis Ltd Use of cannabis to treat migraine
US20160317468A1 (en) * 2015-04-28 2016-11-03 Raman Sankar Uses of cannabidiol for treatment of infantile spasms
CA2985969A1 (en) * 2015-05-13 2016-11-17 One World Cannabis Ltd Use of cannabis to treat fibromyalgia, methods and compositions thereof
MX2018015583A (es) * 2016-06-15 2019-05-16 Ojai Energetics Pbc Metodos y composiciones para reducir el estres oxidativo.

Also Published As

Publication number Publication date
EP3677258A4 (en) 2020-09-09
JP2020530499A (ja) 2020-10-22
EP3677258A1 (en) 2020-07-08
AU2017429312B2 (en) 2022-03-24
CA3073576A1 (en) 2019-03-07
JP6963719B2 (ja) 2021-11-10
WO2019041239A1 (zh) 2019-03-07
US11452707B2 (en) 2022-09-27
EP3677258B1 (en) 2022-02-09
AU2017429312A1 (en) 2020-04-16
US20200360336A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
KR102607599B1 (ko) 인플루엔자의 치료 방법
Wang et al. Inhibition of the infectivity and inflammatory response of influenza virus by Arbidol hydrochloride in vitro and in vivo (mice and ferret)
Jin et al. Oroxylin A suppresses influenza A virus replication correlating with neuraminidase inhibition and induction of IFNs
KR101317318B1 (ko) 신종인플루엔자, 조류인플루엔자, 일반 및 독감감기, ｓａｒｓ 바이러스 억제 효능을 갖는 오배자 추출물 또는 이로부터 분리된 화합물을 유효성분으로 함유하는 약학 조성물
KR100962334B1 (ko) 울금으로부터 얻은 조류, 돼지 인플루엔자 및 신종플루에 대한 항바이러스제
Galabov et al. Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice
KR101782532B1 (ko) 백지 추출물 또는 이로부터 분리된 퓨라노쿠마린을 함유하는 조류 인플루엔자, 돼지 인플루엔자 또는 코로나 바이러스의 예방 또는 치료용 조성물
AU2017429312B2 (en) Uses of cannabidiol in preparation of drugs for resisting against influenza
EP4329743A1 (en) Pyruvate esters for the treatment of viral diseases
CN109419786B (zh) 大麻二酚在制备抗流感的药物中的用途
CN117838696A (zh) 鲁索替尼在制备治疗流感病毒感染的药物中的应用
KR101731607B1 (ko) 음양곽 추출물을 유효성분으로 함유하는 항 바이러스용 조성물
US11433080B2 (en) Antiviral treatment
Sun et al. Sodium taurocholate hydrate inhibits influenza virus replication and suppresses influenza a Virus-triggered inflammation in vitro and in vivo
CA2465062C (en) Preventive and/or therapeutic agent for viral infection
Yu Efficacy of (R)-6-adamantane-derivatives of 1, 3-oxazinan-2-one and piperidine-2, 4-dione in the treatment of mice infected by the A/California/04/2009 influenza virus
CN114288297A (zh) 千金藤素在制备抗流感病毒药物中的应用
CN110151767B (zh) Gnf-7在制备治疗流感病毒感染的药物中的应用
KR20230146695A (ko) 인플루엔자 바이러스 억제용 조성물
CN117838698A (zh) 奥拉替尼在制备治疗流感病毒感染的药物中的应用
WO2020216349A1 (zh) 一种肠道病毒抑制剂
CN110292576A (zh) 罗替戈汀在制备治疗或预防流感病毒感染的药物中的应用
CN105832755A (zh) 金丝桃苷和奥司他韦联合在防治h7n9型流感药物中的应用
CN114732821A (zh) 西多福韦的前药在制备防治非洲猪瘟药物中的应用
HK1150338B (en) The use of a traditional chinese medicine composition in the preparation of anti-influenza virus drugs

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200220

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251211

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251212

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260326

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260413

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260713